(NASDAQ: VSTM) Verastem's forecast annual revenue growth rate of 45.28% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 33.02%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.51%.
Verastem's revenue in 2026 is $87,526,000.On average, 11 Wall Street analysts forecast VSTM's revenue for 2026 to be $10,417,512,618, with the lowest VSTM revenue forecast at $8,821,965,915, and the highest VSTM revenue forecast at $11,801,321,997. On average, 11 Wall Street analysts forecast VSTM's revenue for 2027 to be $16,833,026,779, with the lowest VSTM revenue forecast at $11,067,758,125, and the highest VSTM revenue forecast at $25,513,532,599.
In 2028, VSTM is forecast to generate $24,540,881,242 in revenue, with the lowest revenue forecast at $15,921,958,562 and the highest revenue forecast at $34,509,199,193.